Aktivne farmacevtske sestavine
| Progestagen in estrogen | |||
| Ime izdelka | Specifikacija | Odobreno | št. CAS |
| progesteron | CP/EP/USP/JP | CEP/EU-GMP/FDA | 57-83-0 |
| Pregnenolon | V hiši |
košer | 145-13-1 |
| Medroksiprogesteron Acetat | CP/EP/USP/JP | DMF/GMP | 71-58-9 |
| Megestrol acetat | CP/EP/USP | DMF v postopku | 595-33-5 |
| Mifepriston | CP/IP | DMF/GMP | 84371-65-3 |
| Ciproteron acetat | CP/EP/IP/KP | CEP/TGA/EU-GMP | 427-51-0 |
| levonorgestrel | CP/EP/USP/IP | CEP/GMP | 797-63-7 |
| Noretisteron |
CP/EP/USP/JP |
DMF v postopku |
68-22-4 |
| Noretisteronacetat |
EP/USP |
DMF v postopku |
51-98-9 |
| Noretisteron enantat |
V hiši |
V okviru raziskav in razvoja |
3836-23-5 |
| Drospirenon | EP/USP | DMF | 67392-87-4 |
| Gestoden | CP/EP | DMF/GMP | 60282-87-3 |
| Estradiol | CP/EP/USP/KP | DMF/GMP/WC | 35380-71-3 |
| Estriol | CP/EP/USP | V okviru raziskav in razvoja | 50-27- 1 |
| Etinilestradiol | CP/EP/USP | GMP | 57-63-6 |
| Estradiol Valerat | CP/EP/USP/KP | DMF | 979-32-8 |
| Estradiol cipionat |
USP | DMF v postopku |
313-06-4 |
| Promestriene |
V hiši |
V okviru raziskav in razvoja |
39219-28-8 |
| Tibolon | CP/EP | DMF/GMP | 5630-53-5 |
| Dienogest | EP | CEP/GMP | 65928-58-7 |
| Fulvestrant | EP/USP | V okviru raziskav in razvoja | 129453-61-8 |
| Eksemestan | CP/EP/USP | V okviru raziskav in razvoja | 107868-30-4 |
| Androgen | |||
| Ime izdelka | Specifikacija | Odobreno | št. CAS |
| Finasterid | CP/EP/USP | CEP/FDA/PMDA/GMP | 98319-26-7 |
| Dutasterid | EP/USP | CEP/FDA | 164656-23-9 |
| Abirateronacetat | CP/USP | DMF/GMP/WC | 154229-18-2 |
| darolutamid |
V hiši |
V okviru raziskav in razvoja |
1297538-32-9 |
| Testosteron | CP/EP/USP | CEP/FDA/WC | 58-22-0 |
| Testosteron undekanoat | CP | DMF/WC | 5949-44-0 |
| Testosteron Cypionate | USP | DMF | 58-20-8 |
| Testosteron Enanthate |
USP/JP | V okviru raziskav in razvoja |
315-37-7 |
| Testosteron propionat |
CP/EP/USP/JP |
V okviru raziskav in razvoja |
57-85-2 |
| DHEA | FP/V hiši | DMF/WC/Košer | 53-43-0 |
| Klaskoteron | V hiši | DMF v postopku | 19608-29-8 |
| Kortikalni hormon | |||
| Ime izdelka | Specifikacija | Odobreno | št. CAS |
| Budezonid | CP/EP/USP/JP | CEP/FDA/GMP | 51333-22-3 |
| Desonid | CP/USP | DMF/GMP | 638-94-8 |
| Eplerenon | EP | CEP v postopku | 107724-20-9 |
| Metilprednizolon | CP/EP/USP/JP | DMF/GMP | 83-43-2 |
| Metilprednizolon Hemisukcinat | CP/EP/USP | DMF/GMP | 2921-57-5 |
| Flutikazon propionat | CP/EP/USP | DMF | 80474- 14-2 |
| Flutikazon furoat | CP/EP | DMF v postopku | 397864-44-7 |
| Mometazon furoat |
CP/EP/USP |
DMF v postopku |
brezvodni (83919-23-7) Monohidrat (141646-00-6) |
| Deflazakort |
V hiši |
V okviru raziskav in razvoja |
14484-47-0 |
| drugi | |||
| Ime izdelka | Specifikacija | Odobreno | št. CAS |
| okskarbazepin | CP/EP/USP/IP | CEP/FDA/GMP | 28721-07-5 |
| Eslikarbazepinacetat | CP/USP | DMF | 236395- 14-5 |
| ganciklovir | CP/EP/USP | DMF/GMP | 82410-32-0 |
| Valganciklovir hidroklorid | USP/EP | CEP v postopku | 175865-59-5 |
| Oseltamivir fosfat | CP/EP/USP | DMF | 204255- 11-8 |
| Baloxavir Marboxil | V hiši | V okviru raziskav in razvoja | 1985606-14-1 |
| Revefenacin | V hiši | DMF | 864750-70-9 |
| Mirabegron | CP/EP | DMF | 223673-61-8 |
| Vibegron |
V hiši |
V okviru raziskav in razvoja |
1190389-15-1 |
| Escitalopram oksalat | CP/EP/USP | DMF v postopku | 219861-08-2 |
| Citalopram hidrobromid |
CP/EP/USP |
DMF v postopku |
59729-32-7 |
| kariprazin hidroklorid | V hiši | DMF | 1083076-69-0 |
| Lasmiditan sukcinat | V hiši | DMF | 439239-92-6 |
| lulikonazol | V hiši | DMF | 187164-19-8 |
| Nintedanib Esylate |
V hiši |
FDA/DMF/WC |
656247-18-6 |
| Apalutami | V hiši | DMF | 956104-40-8 |
| Tadalafil | CP/EP/USP | V okviru raziskav in razvoja | 171596-29-5 |
| Relugoliks | V hiši | DMF v postopku | 737789-87-6 |
| Ruksolitinib fosfat |
V hiši |
DMF v postopku |
1092939-17-7 |
| Abemaciklib |
V hiši |
V okviru raziskav in razvoja |
1231929-97-7 |
| floroglucinol | CP/EP | DMF | 108-73-6 |
| 1,3,5-trimetoksibenzen |
CP/notranji |
GMP |
621-23-8 |
| Ursodeoksiholna kislina | EP/USP/JP | V okviru raziskav in razvoja | 128-13-2 |
| Tauroursodeoksiholna kislina |
V hiši |
V okviru raziskav in razvoja |
14605-22-2 |
| holesterol |
CP/EP/USP/JP |
V okviru raziskav in razvoja |
57-88-5 |
| Omega-3-kislinski etil etri 90 |
EP/USP |
DMF v postopku |
—— |
| Srednjeverižni trigliceridi |
CP/USP/EP |
DMF |
—— |
| Benzalkonijev klorid |
USP/EP/JP |
CEP v postopku |
8001-54-5 |
| Oljčno olje (za injiciranje) |
CP/USP/EP/JP |
DMF v postopku |
8001-25-0 |
| Jajčni fosfolipidi (za injiciranje) |
CP/USP/EP |
DMF |
93685-90-6 |
| Prigrizek |
V hiši |
DMF v postopku |
203787-91-1 |
Abiraterone Acetate ima specifikacije CP, USP. DMF, WC na voljo.
Drospirenon ima specifikacije EP, USP. DMF odobreno.
Medroksiprogesteron acetat ima USPãEPã IPãJP in KP. DMF, GMP je na voljo.
Okskarbazepin ima specifikacije CP, EP in USP. Na voljo sta CEP in DMF, odobren GMP.
Ganciklovir ima specifikacije CP, EP, USP. DMF in GMP odobren.
Nintedanib Esylate ima interne specifikacije. DMF je na voljo.